Abstract: Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes. However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in diabetes pathogenesis such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen [HLA] gene, miRNA gene and hepatocyte growth factor [HGF] gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies and gene therapy for type 1 diabetes management.
Journal: Pharmaceutical Nanotechnology
Keywords: Autoimmunity; Immunotherapy; Nanocarriers; Stem cell; Tolerance; Type 1 diabetes
![[Review Paper] Nanobiotechnology-Modified Cellular and Molecular Therapy as a Novel Approach for Autoimmune Diabetes Management](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg9bT7e32NlrACHdc9x6NbfeGRXDeXErgX87JzQqX2b3enI1JRAGEVKF_gE_9KKHTUIGmD0kzWUmnNTfplz75G988Gs9Uq9b0SUN0Im7QWS0DB2xTtO5VCYDXFlejs0-v6qUiaiU51DeV_jsN051whXmCk64oMYV7Pld35dRoEGOkKjSVEwBOKtclPXaw/s72-c/pnt.jpeg)